Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-agent Becotatug Vedotin as Adjuvant Therapy for High-risk Locoregional Advanced Nasopharyngeal Carcinoma: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 2 Trial

NCT07303283 is registered in ClinicalTrials.gov with Kai Hu as lead sponsor.

NCT NCT07303283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07303283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-agent Becotatug Vedotin as Adjuvant Therapy for High-risk Locoregional Advanced Nasopharyngeal Carcinoma: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 2 Trial
Lead sponsor
Kai Hu
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
August 31, 2033
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, locoregionally advanced nasopharyngeal carcinoma, nasopharyngeal carcinoma (npc)